Calmark relaunches Neo-Bilirubin in Finland
Calmark Sweden AB announces today that they have started a relaunch of the product Neo-Bilirubin in Finland together with its distributor Triolab Oy. Triolab has placed an order of less economic value which has been delivered. The product will be exhibited at Lab Quality Days, an exhibition held in Helsinki during this week.
Calmark Sweden Ab already has a distributor agreement with Triolab Oy in Finland. The collaboration has now intensified after Calmark's product Neo-Bilirubin can also be used for capillary sampling. The product will be exhibited at a fair in Helsinki during the week.
"According to the distributor, a number of hospitals and clinics have shown interest in using a near-patient solution for bilirubin tests on newborns," comments CEO Anna Söderlund. "We are very happy about the committed work that Triolab does.”
For more information about Calmark Sweden AB, please contact:
Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se
www.calmark.se
Calmark Sweden AB is a medical technology company that manufactures and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, is CE marked and measures the bilirubin level in whole blood for jaundice detection in newborns. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product offers a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.
Tags: